GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » LifeMD Inc (NAS:LFMD) » Definitions » Altman Z-Score

LifeMD (LifeMD) Altman Z-Score

: 1.32 (As of Today)
View and export this data going back to 2020. Start your Free Trial

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of 1.32 is in distress zone. This implies bankruptcy possibility in the next two years.

LifeMD has a Altman Z-Score of 1.32, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for LifeMD's Altman Z-Score or its related term are showing as below:

LFMD' s Altman Z-Score Range Over the Past 10 Years
Min: -68.35   Med: -8.34   Max: 1.32
Current: 1.32

During the past 13 years, LifeMD's highest Altman Z-Score was 1.32. The lowest was -68.35. And the median was -8.34.


LifeMD Altman Z-Score Historical Data

The historical data trend for LifeMD's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LifeMD Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.52 -13.76 -2.49 -11.16 0.40

LifeMD Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Altman Z-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.16 -7.19 -5.29 -3.46 0.40

Competitive Comparison

For the Health Information Services subindustry, LifeMD's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LifeMD Altman Z-Score Distribution

For the Healthcare Providers & Services industry and Healthcare sector, LifeMD's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where LifeMD's Altman Z-Score falls into.



LifeMD Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

LifeMD's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.1338+1.4*-3.6638+3.3*-0.2533+0.6*7.5274+1.0*2.6085
=1.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was $58.5 Mil.
Total Current Assets was $42.6 Mil.
Total Current Liabilities was $34.8 Mil.
Retained Earnings was $-214.3 Mil.
Pre-Tax Income was -2.794 + -5.283 + -5.891 + -3.442 = $-17.4 Mil.
Interest Expense was -0.623 + -0.714 + -0.996 + -0.264 = $-2.6 Mil.
Revenue was 44.86 + 38.614 + 35.947 + 33.126 = $152.5 Mil.
Market Cap (Today) was $398.3 Mil.
Total Liabilities was $52.9 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(42.604 - 34.782)/58.481
=0.1338

X2=Retained Earnings/Total Assets
=-214.265/58.481
=-3.6638

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-17.41 - -2.597)/58.481
=-0.2533

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=398.312/52.915
=7.5274

X5=Revenue/Total Assets
=152.547/58.481
=2.6085

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

LifeMD has a Altman Z-Score of 1.32 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


LifeMD  (NAS:LFMD) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


LifeMD Altman Z-Score Related Terms

Thank you for viewing the detailed overview of LifeMD's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


LifeMD (LifeMD) Business Description

Traded in Other Exchanges
N/A
Address
236 Fifth Avenue, Suite 400, Fourth Floor, New York, NY, USA, 10001
LifeMD Inc is a direct-to-patient telehealth company that provides a smarter, cost-effective, and more convenient way of accessing comprehensive, virtual healthcare. Its telehealth platform seamlessly integrates a clinician-centric electronic medical record (EMR) system, proprietary algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. In addition to telehealth offerings, the company sells nutritional supplements and other over-the-counter products. The company has two operating segments: Telehealth and WorkSimpli. The company generates the majority of its revenue from the Telehealth segment.
Executives
Bertrand Velge director BARNHOUSE FARM, BARNHOUSE LANE BROOKLAND, ROMNEY MARSH, KENT X0 TN299TR
William J Febbo director, other: Consultant 600 CALIFORNIA ST., 9TH FLOOR, SAN FRANCISCO CA 94108
Nicholas P Alvarez officer: Chief Acquisition Officer C/O LIFEMD, INC., 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Eric Harold Yecies officer: CCO and General Counsel C/O LIFEMD, INC., 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Brad Michael Roberts officer: Chief Operating Officer 300 CHAFFORD COURT, SIMPSONVILLE SC 29681
Justin Schreiber director, 10 percent owner, officer: President, Immudyne PR 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Stefan Galluppi director, officer: Chief Operating Officer C/O LIFEMD, INC, 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Joan Larovere director C/O LIFEMD, 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Jessica Friedeman officer: Chief Marketing Officer C/O LIFEMD, 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Kathleen E Walsh director C/O LIFEMD, INC., 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Piyush Jindal director C/O LIFEMD, INC., 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Joseph Ditrolio director C/O LIFEMD, INC., 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Maria E. Stan officer: Principal Accounting Officer 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Dennis Wijnker officer: Chief Technology Officer 536 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Naveen Bhatia director 823 GREENTREE RD, PACIFIC PALISADES CA 90272